Daily Chart:
http://stockcharts.com/h-sc/ui?s=CTIC&p=D&b=5&g=0&id=p46247955359Weekly Chart:
http://stockcharts.com/h-sc/ui?s=CTIC&p=W&b=5&g=0&id=p52731907171News:
https://finance.yahoo.com/quote/CTIC/press-releases?p=CTICBusiness Summary: CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral multikinase inhibitor with activity against Janus Kinase 2 and FMS-like tyrosine kinase, which is in Phase III clinical trials for the treatment of myelofibrosis.
In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II/III clinical trials for the treatment of acute myeloid leukemia; and Opaxio, a chemotherapeutic agent, which is in Phase III clinical trials for the treatment of various solid tumors, including non-small cell lung, ovarian, breast, and prostate cancers. The company has development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA for the development and commercialization of pacritinib for use in oncology and other therapeutic areas.
The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014.
CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Company Website:
https://www.ctibiopharma.com
Home
Help
Search
Contact
Login
Register